Healthcare

Mega trends have made the healthcare industry one of the most attractive growth sectors in the stock market. Examples of these trends are population ageing and the Westernization of lifestyles as reflected in the rise of obesity rates and stress worldwide. Healthy returns for investors. 

Investment Case Healthcare

All lights are green for investors in the healthcare sector. Numerous factors are powering a steady increase in demand for health care. First and foremost, the rise in life expectancy around the world. That and the global adoption of Westernized lifestyles are leading to a dramatic increase in diseases typical of modern civilization – obesity, for example, or diabetes, Alzheimer’s and cancer.

While healthcare spending in developed countries has risen independently of the economic cycle, healthcare systems in transition economies such as China, India, Indonesia and Russia have been experiencing rapid growth. Governments in these countries are establishing and expanding their healthcare systems on the one hand while a growing middle class is increasing its consumption of private healthcare services on the other.

Per capita spending on healthcare in industrialized countries has approximately doubled since 1995. In China it has soared almost 20-fold during the same period, albeit from a very low initial level. Even after this dizzying growth, per capita healthcare spending in China is still only a few hundred dollars a year, well below the average levels in the West. So there is still considerable scope for growth.

Diabetes epidemic

The widespread adoption of Western lifestyles has raised the number of diabetics worldwide to 400 million, quadruple the number from 1980. Besides poor eating habits, a lack of physical activity and higher stress levels are the primary causes of the rapid spread of this epidemic disease.

Being overweight significantly increases the risk of developing diabetes. According to some estimates, 40% of the adult population in the US is obese (BMI > 30). And the US is not alone in this regard. Qatar claims the dubious distinction of having the highest percentage of diabetics in the world – 24% of the population. In China more than 100 million people have developed diabetes. Lifestyle change is clearly, then, a global phenomenon.

Biotechnology – A driver of innovation in medicine

Every second drug approved by regulators today has emerged from the labs of a biotech company. Innovation power is fueling the biotech sector's annual sales, which now exceed USD 130 billion, and it has produced revolutionary breakthroughs, two examples being HIV and hepatitis C treatment regimes. Fifty years ago only a third of all cancer patients had a chance of survival; today two-thirds of all patients survive this once-deadly disease. In fact, the survival rate is likely to climb significantly higher still, thanks to the latest breakthroughs in immuno-oncology and gene therapy. Before biotech firms began intensively researching orphan diseases there were few treatments options for these rare diseases. In the meantime orphan drugs have become a billion dollar business. 

Medtech – Helping to improve efficiency in healthcare systems

10% of world GDP is spent on healthcare. Half of this expenditure is financed by the public sector. Budgetary constraints are forcing healthcare systems to become more efficient and innovative medical technology companies are focusing exactly on making that happen. Modern technology such as minimally invasive surgical procedures are more effective and shorten the recovery period.

Such innovation not only relieves patient pain and suffering, it also reduces costs. Groundbreaking medical technology is highly appreciated by doctors and patients alike and it is attracting attention from investors too. The inexpensively valued companies in the medtech sector with their comparatively conservative risk/reward profiles are especially appealing to cautious investors. Innovation skills in the medtech industry are demonstrably high while both the costs and the hurdles that must be cleared to have a product approved by regulators are lower than in the biotech industry.

Generic drugs – Biosimilars ready for takeoff

Makers of generic drugs are also benefiting from the general pressure to improve efficiency in health care. Low-priced copycat drugs are an answer to spiraling healthcare expenditure. Generics enter the market after a brand-name product loses patent exclusivity. Meanwhile, the next growth driver is already ready to enter the scene – «biosimilars» or drugs made from living organisms that are highly similar to a brand-name reference product. IMS Health predicts that sales of biosimilars will grow ten-fold during the next five years. 

Asia – Growth potential waiting to be tapped

Greater treatment efficiency is not only an issue in industrialized countries, it is spawning to new medical solutions in less developed countries as well. Increasing prosperity in emerging markets is creating new and substantial sales potential in markets that are as yet largely untapped. Highly profitable growth beckons for innovative players. 

Profitable investments

These are all positive factors fueling fast top-line growth rates. Sales in some parts of the health care industry have been growing at a double-digit pace year after year. The growth of the health care industry as a whole also stands out: At 5% p.a., the sector’s long-term growth is twice as fast as gross world product.

Our expertise

Finding the most promising stocks in the highly dynamic biotech sector is no easy undertaking. Financial know-how is needed, as is a thorough understanding of a complex and vast spectrum of research within the fields of medicine, biochemistry and biology. BB Biotech specialists expertly cover all three areas. An interdisciplinary dialog is constantly maintained not only within the team but also between the team and the expert members of the Board of Directors and external specialists such as doctors and analysts. This ensures that only the most attractive biotech stocks end up in BB Biotech's portfolio.

Team BB Biotech AG

Daniel Koller
Dr. Daniel Koller, Head
  • Since 2004 with Bellevue Asset Management as head of the investment company BB Biotech Ltd
  • 2001 - 2004 equity4life Asset Management Ltd, investment manager
  • 2000 - 2001 UBS Warburg, equity analyst
  • Master's degree in Biochemistry of the Swiss Federal Institute of Technology (ETH) Zurich
  • PhD in Biotechnology of the Swiss Federal Institute of Technology (ETH) Zurich and Cytos Biotechnology Ltd, Zurich
Felicia Flanigan
Felicia Flanigan, Portfolio Manager
  • Since 2004 with Bellevue Asset Management as senior biotech analyst and Head Bellevue Research Inc
  • 1999 - 2004 Adams, Harkness & Hill, biotech equity analyst
  • 1991 - 1999 SG Cowen, biotech equity analyst
  • MBA, Suffolk University, Boston
  • BA in Communications, Boston College
Stephen Taubenfeld
Dr. Stephen Taubenfeld, Portfolio Manager
  • Since October 2013 with BB Biotech as Portfolio Manager specializing in neurologic and psychiatric diseases
  • 2009-2013 Iguana Healthcare Partners, Senior Analyst and Founding Partner
  • 2008-2009 Merlin BioMed Group, Consultant
  • 2004-2008 Mount Sinai Hospital, New York, National Institutes of Health M.D./Ph.D. Fellow in Neuroscience
  • M.D. and Ph.D. in Neuroscience, Brown University School of Medicine
Dallas Webb
Dallas Webb, Portfolio Manager
  • Since 2006 with Bellevue Asset Management as analyst/portfolio manager biotech
  • 2004-2006 Standford Group Company, senior vice president, equity analyst
  • 2003-2004 Sterling Financial Investment Group, equity analyst
  • 2002-2003 Adams, Harkness & Hil, vice president, associate analyst
  • MBA, Texas Christian University
  • BA in Microbiology and Zoology, Louisiana State University
Christian Koch
Dr. Christian Koch, Portfolio Manager
  • Analyst and Portfolio Manager at BB Biotech since 2014
  • 2013-2014 Sell-side Pharma & Biotech Equity Analyst at Bank am Bellevue in Küsnacht
  • 2010-2013 Research Associate at the Institute of Pharmaceutical Sciences, ETH Zurich
  • Doctorate in Chemoinformatics & Computational Drug Design, ETH Zurich
  • Degree in Bioinformatics, Goethe University Frankfurt
Maurizio Bernasconi
Dr. Maurizio Bernasconi, Portfolio Manager
  • Since 2017 Investment Management Team BB Biotech
  • 2014-2017 with Bank am Bellevue as financial analyst of the Pharma/Biotech sector
  • 2014: Chemist at SIGA Manufacturing, Ruswil, Zurich
  • 2009–2013: PhD in organic chemistry at the University of Basel
  • 2004–2009: master’s degree in chemistry, Swiss Federal Institute of Technology (ETH), Zurich
Jan Bootsma
Jan Bootsma, Portfolio Management
  • 1995 - present Asset Management BAB N.V., Curaçao, Managing Director / Portfolio Management
  • 1990 - 1995 CITCO Account Manager Securities Administration
  • 1985 - 1989 Multilift, Head Administration
  • 1984 - 1985 Higher Economic Education (HEAO)
Hugo Van Neutegem
Hugo Van Neutegem, Portfolio Management
  • Since 2001 BB Biotech subsidiary, Curaçao, Chairman
  • 2000 - 2001 CITCO, Managing Director
  • 1992 - 2000 Ernst & Young, Netherlands and the Netherlands Antilles
  • 1984 - 1992 Tax law, University of Leiden, the Netherlands
Natalie Isidora-Kwidama
Natalie Isidora-Kwidama, Portfolio Management
  • Since 2007 Asset Management BAB N.V., Curaçao, Portfolio Management
  • 2006 - 2007 NMT Services N.V., Account Manager / Securities Administrator
  • 1997 - 2006 Decro Trust N.V., Securities Administration for large Dutch investment compan
  • 1992 - 1996 CITCO, Securities Administration
  • 2004 - 2005 Modern business administration
Rudy Le Blanc
Rudy Le Blanc, Portfolio Management
  • Board member and managing director of the BB Biotech branch office in Curaçao since 2013
  • Various executive positions with the National Laboratory of Curaçao
  • Operational director and still partner at a local Curaçao private medical laboratory
  • Degree in medical science from the Emory University in Atlanta, USA
Silvia Schanz
Dr. Silvia Schanz, Investor Relations
  • Since 2012 with Bellevue Asset Management as Director Investor Relations for the investment company BB Biotech AG
  • 2011 – 2012 UBS Wealth Management, Buy-side Financial Analyst, Global Healthcare
  • 2008 – 2011 Vontobel Investment Banking, Sell-side Financial Analyst, Pharmaceuticals and Biotechnology
  • Certified International Investment Analyst (CIIA)
  • PhD / doctorate in Biochemistry of the Swiss Federal Institute of Technology (ETH) Zurich
  • Master in Biochemistry, minor in Business Administration of the University Freiburg
Claude Mikkelsen
Claude Mikkelsen, Investor Relations
  • With Bellevue Asset Management as Senior Sales Germany since 2012
  • 2011 – 2012 Head of Branch Office, Dr. Kohlhase Asset Management, Hamburg
  • 2004 – 2011 Client Relationship Manager, UBS Deutschland AG, Frankfurt
  • 1997 – 2004 Sales Associate, JPMorgan Asset Management, Frankfurt, Luxemburg, London
  • Banking Administration (Frankfurt School of Finance & Management)
  • MBA from Henley Business School, UK
Maria-Grazia Iten-Alderuccio
Maria-Grazia Iten-Alderuccio, Investor Relations
  • Since 2007 with Bellevue Asset Management as Director Investor Relations BB Biotech AG
  • 2004–2007 Citco Fund Advisors, senior relationship manager
  • Master's degree in Linguistics from the University of Lausanne and Università degli Studi di Firenze, Italy
  • Daniel Koller
  • Felicia Flanigan
  • Stephen Taubenfeld
  • Dallas Webb
  • Christian Koch
  • Maurizio Bernasconi
  • Jan Bootsma
  • Hugo Van Neutegem
  • Natalie Isidora-Kwidama
  • Rudy Le Blanc
  • Silvia Schanz
  • Claude Mikkelsen
  • Maria-Grazia Iten-Alderuccio

Team BB Healthcare Trust plc

Daniel Koller
Dr. Daniel Koller, Portfolio Manager
  • Since 2004 with Bellevue Asset Management as head of the investment company BB Biotech Ltd
  • 2001 - 2004 equity4life Asset Management Ltd, investment manager
  • 2000 - 2001 UBS Warburg, equity analyst
  • Master's degree in Biochemistry of the Swiss Federal Institute of Technology (ETH) Zurich
  • PhD in Biotechnology of the Swiss Federal Institute of Technology (ETH) Zurich and Cytos Biotechnology Ltd, Zurich
Paul Major
Paul Major, Portfolio Manager
  • Since 2016 Portfolio Manager BB Healtcare Trust plc
  • 2004-2016 Research Partner at Redburn
  • 1996-2003 Analyst and Corporate Financier at UBS Warburg
  • Master in Biochemistry (University of Bath)
Claude Mikkelsen
Claude Mikkelsen, Investor Relations
  • With Bellevue Asset Management as Senior Sales Germany since 2012
  • 2011 – 2012 Head of Branch Office, Dr. Kohlhase Asset Management, Hamburg
  • 2004 – 2011 Client Relationship Manager, UBS Deutschland AG, Frankfurt
  • 1997 – 2004 Sales Associate, JPMorgan Asset Management, Frankfurt, Luxemburg, London
  • Banking Administration (Frankfurt School of Finance & Management)
  • MBA from Henley Business School, UK
Brett Darke
Brett Darke, CFA, Portfolio Manager
  • Since 2017 member of the Investment Team BB Healthcare Trust plc
  • 2006 – 2017 Analyst life sciences and healthcare sector at TT International for long-only and long/short funds.
  • 2001 – 2006 Corporate finance at Merrill Lynch and Bear Stearns
  • Masters degree in Medicine and Management studies from Cambridge University
  • CFA Charterholder
  • Daniel Koller
  • Paul Major
  • Claude Mikkelsen
  • Brett Darke

The BB Adamant Healthcare Funds & Mandates Team consists of an interdisciplinary mix of experts with many years of experience in the fields of biotechnology, medical technology, and generics. Many of our experts earned a degree in biochemistry or other natural sciences before furthering their education in financial or economic fields. The experienced team covers a universe of 600 listed companies in the healthcare sector using a variety of quantitative and qualitative parameters in its fundamental analyses. Regular meetings with company executives and participation in conferences for healthcare specialists and investment professionals are also important for the research and investment process. 

Team BB Adamant Healthcare (Funds & Mandates)

Cyrill  Zimmermann
Dr. Cyrill Zimmermann, Head
  • Since 2015 Head Healthcare Funds & Mandates, Member of the Executive Board
  • 2001-2014 Co-founder and CEO of Adamant Biomedical Investment AG
  • 1996-2000 Member of the Management Team BB Medtech at Bellevue Asset Management AG
  • 1993-96 Advisor for institutional clients and former assistant to the Executive Management at Credit Suisse
  • Dr.oec.publ. (University of Zurich)
Christian Lach
Dr. Christian Lach, Portfolio Manager
  • Since 2015 Senior Portfolio Manager Healthcare Funds & Mandates
  • 2008-2014 Senior Portfolio Manager in Biotech at Adamant Biomedical Investment AG
  • 2001-2008 Member of the Management Teams BB Biotech and BB Medtech at Bellevue Asset Management AG
  • Dr. oec. HSG, dipl. natw. ETH
Stefan  Blum
Stefan Blum, CEFA, Portfolio Manager
  • Since 2008 with Bellevue Asset Management as lead portfolio manager of the BB Adamant Medtech & Services (Lux) Fund
  • 2004 - 2008 Sonova, head investor relations
  • 2000 - 2004 Obtree Technologies Inc., finance and investor relations
  • 1996 - 2000 Bank Sarasin, medtech analyst
  • Master’s degree in Business Economics, University of St. Gallen (HSG), CEFA charterholder
Marcel  Fritsch
Marcel Fritsch, Portfolio Manager
  • Since 2008 with Bellevue Asset Management as portfolio manager of the BB Adamant Medtech & Services (Lux) Fund
  • 2004 - 2008 Deloitte & Touche LLP, business consultant with focus on the medtech and pharmaceutical sectors
  • Master’s degree in Business Economics, University of St. Gallen (HSG)
Oliver Kubli
Oliver Kubli, CFA, Portfolio Manager
  • Since 2015 Managing Director, Head Portfolio Management Healthcare Funds & Mandates
  • 2008-2014 Member of the Management Team and Head Portfolio Management at Adamant Biomedical Investment AG
  • 2000-2007 Senior Portfolio Manager at Zürcher Kantonalbank
  • Bachelor of Business Administration, University of Applied Sciences, Winterthur, CFA
Samuel Stursberg
Samuel Stursberg, CFA, Portfolio Manager
  • Since 2015 Head Research Healthcare Funds & Mandates
  • 2007-2014 Head Research at Adamant Biomedical Investment AG
  • 2005-2007 Stock analysis medtech and biotech at Bank Sarasin
  • 2001-2005 Sustainable Asset Management, stock analysis in healthcare
  • M.Sc University of Basel, MBA HSG, CFA
Hanns Frohnmeyer
Dr. Hanns Frohnmeyer, Portfolio Manager
  • Since 2017 Senior Portfolio Manager Healthcare Funds & Mandates
  • 2011 – 2015 Aeris Capital, Executive Director Life Science
  • 2001 – 2011 LBBW, Head of Life Science Analyst Team
  • 1994 – 2001University Freiburg, Assistant professor (Molecular biology)
Marvin Ng
Marvin Ng, MBA, Consultant
  • Consultant Bellevue Asset Management in Asia
  • Since 2002 DN Venture Partners, Singapore/Germany, Director and consultant to life sciences organisations on business development in Asia
  • Since 2002 Greener Grass Communications, Singapore, Director and consultant to technology companies on public relations matters
  • First Class Honours Degree in Microbiology, University of British Columbia (Canada), Masters in Business Administration, Simon Fraser University (Canada)
Michael  Mullen
Prof. Michael Mullen, CFA, Consultant
  • Consultant Bellevue Asset Management AG in the United States
  • Since 2005 Tarvos Capital Management, LLC, Boston / Basel, Managing Director and founder
  • 1999-2005 President of Bellevue’s U.S. research operation, Co-manager of lead products: BB Biotech and BB Medtech
  • Graduated from Fordham University with a B.S. in accounting and finance
  • MBA from Indiana University Graduate School of Business
  • CFA, member of the CFA Institute
Zahide Donat
Zahide Donat, Portfolio Manager
  • Since2015 Junior Portfolio Manager
  • 2014-2015 Credit Suisse AG, Banking Operations Specialist in Fixed Income
  • 2010-2013 Migros Bank AG, Relationship Manager
  • Bachelor of Science ZFH in Business Administration (Focus Banking and Finance)
Sandra Muino
Sandra Muino, Operations & Finance
  • Since 2015 Operations& Finance at Bellevue Asset Management
  • 2002-2014 Compliance Officer Adamant Biomedical Investments AG
  • Professional Bachelor in Business Administration
Christina Wirz
Christina Wirz, Office Manager/Assistant
  • Since 2015 at Bellevue Asset Management
  • 2012-2015 Bank Vontobel, Administration team Investment Banking
  • 1999-2012 UBS AG, Team Global Wealth Management & Business Banking
  • 1984-1994 Jelmoli SA, Projectleader and Product Management
Alexandra  Keller
Alexandra Keller, Office Manager/Assistant
  • Since 2015 at Bellevue Asset Management
  • 2012-2015 at Adamant Biomedical Investments AG
  • Commercial employee with federal diploma in Banking
  • Cyrill  Zimmermann
  • Christian Lach
  • Stefan  Blum
  • Marcel  Fritsch
  • Oliver Kubli
  • Samuel Stursberg
  • Hanns Frohnmeyer
  • Marvin Ng
  • Michael  Mullen
  • Zahide Donat
  • Sandra Muino
  • Christina Wirz
  • Alexandra  Keller

The Bellevue Group has over 20 years of experience investing in healthcare companies and has raised and invested over USD 500 mn in healthcare venture capital. Our goal is to maximize the returns to our investors. To achieve this goal, we combine hard working, hands-on experience, active networking, and deep sector knowledge with a focus on value creation. BB Biotech Ventures is a healthcare-dedicated venture capital firm. We manage funds (limited partnerships) that invest in private companies developing and marketing drugs and medical devices or providing healthcare services. 

Team Healthcare Private Equity

Martin  Münchbach
Dr. Martin Münchbach, Investment Advisor
  • Since 2004 with Bellevue Asset Management as a senior investment advisor biotech ventures
  • Various board assignments with biotech companies in Switzerland and the US
  • 1999 - 2004 NMT and HBM BioVentures/BioMedinvest, investment manager venture capital
  • 1998 - 1999 Sanofi-Synthélabo, strategic marketing
  • PhD in Protein Chemistry, Swiss Federal Institute of Technology (ETH) Zurich, MSc in Biochemistry and a Master's degree in Industrial Engineering and Management from the Swiss Federal Institute of Technology (ETH) Zurich, Studies at the Eberhard Karls Universitity of Tubingen, Germany
Klaus Breiner
Dr. Klaus Breiner, Investment Advisor
  • Since 2004 with Bellevue Asset Management as senior investment advisor venture capital
  • 2001 - 2004 Global Life Science Ventures, investment manager venture capital
  • 2000 - 2001 Booz Allen & Hamilton, management consultant
  • 1995 - 2000 Scientific research at the Swiss Federal Institute of Technology (ETH) Zurich and at the Center of Molecular Biology of University of Heidelberg / ZMBH, Germany
  • PhD degree in Molecular Biology, University of Heidelberg, Master's degree in Chemistry, University of North Carolina, USA
Dominik Escher
Dr. Dominik Escher, Investment Advisor
  • Since 2017 Senior Investment Advisor Private Equity at Bellevue Asset Management
  • 2009-2016 Vice President Reserarch & Development at Alcon
  • Former founder and CEO of ESBATECh, a Swiss biotech acquired by Alcon in 2009
  • Until 2016 Member of the Global Ophtalmology Leadership and Global Biologics Leadership at Novartis
  • Since 2013 President of the Swiss Biotech Association
  • PhD Molecular Biologist
  • Martin  Münchbach
  • Klaus Breiner
  • Dominik Escher

Our investment solutions

Bellevue Asset Management’s range of healthcare sector investment products is the broadest in Europe and, with the investment company BB Biotech, it has been an active and widely recognized investor in this sector for more than 20 years. The Healthcare Index created by Adamant in 2007 reflects the findings of its fundamental research. It is composed of the 40 most attractive healthcare stocks worldwide and is recalibrated every six months.

Product Date ISIN NO. NAV YTD 1YR 3YR Factsheet

BB Adamant Medtech & Services (Lux)

> I-EUR 20.02.2018 LU0415391514 389.41 1.74% 7.62% 25.71%
  • EN

    • DE
    • EN
> B-CHF 20.02.2018 LU0415391605 278.73 0.17% 15.80% 32.12%
  • EN

    • DE
    • EN
> B-USD 20.02.2018 LU0453818899 311.23 4.45% 24.04% 33.47%
  • EN

    • DE
    • EN
> B-EUR 20.02.2018 LU0415391431 365.21 1.63% 6.83% 22.96%
  • EN

    • DE
    • EN
> HB-EUR 20.02.2018 LU0580275534 325.72 3.55% 18.64% 28.71%
  • EN

    • DE
    • EN
> HB-CHF 20.02.2018 LU0580237955 275.54 3.46% 19.30% 28.63%
  • EN

    • DE
    • EN
> I-GBP 20.02.2018 LU0767969719 312.82 0.99% 10.91% 49.79%
  • EN

    • DE
    • EN
> I-CHF 20.02.2018 LU0415391787 297.08 0.28% 16.65% 35.08%
  • EN

    • DE
    • EN
> I-USD 20.02.2018 LU0453818972 330.41 4.56% 24.94% 36.46%
  • EN

    • DE
    • EN
> T-EUR 20.02.2018 LU0433846515 91.99 1.69% 7.25% 24.43%
  • EN

    • DE
    • EN
> T-CHF 20.02.2018 LU0433846606 105.54 0.24% 16.26% 33.71%
  • EN

    • DE
    • EN

BB Adamant Biotech (Lux)

> I-USD 20.02.2018 LU0415392751 500.50 3.19% 12.54% -7.04%
  • EN

    • DE
    • EN
> B-USD 20.02.2018 LU0415392322 468.57 3.08% 11.71% -9.08%
  • EN

    • DE
    • EN
> B-CHF 20.02.2018 LU0415392595 383.93 -1.14% 4.29% -10.00%
  • EN

    • DE
    • EN
> B-EUR 20.02.2018 LU0415392249 506.64 0.30% -3.78% -16.24%
  • EN

    • DE
    • EN
> I-GBP 20.02.2018 LU0767968745 377.67 -0.33% -0.11% 2.01%
  • EN

    • DE
    • EN
> I-EUR 20.02.2018 LU0415392678 543.17 0.40% -3.07% -14.37%
  • EN

    • DE
    • EN
> I-CHF 20.02.2018 LU0415392835 412.32 -1.04% 5.07% -7.98%
  • EN

    • DE
    • EN

BB Adamant Global Biotech (CH)

> AA-CHF 20.02.2018 CH0113817065 2,925.57 -1.34% 3.74% -14.48%
  • EN

    • DE
    • EN
> D-CHF 20.02.2018 CH0113817123 3,056.47 -1.26% 4.37% -12.91%
  • EN

    • DE
    • EN

BB Adamant Healthcare Index (Lux)

> I-USD 20.02.2018 LU1477742818 172.17 3.32% 28.82% n.a.
  • EN

    • DE
    • EN
> B-USD 20.02.2018 LU1477742909 170.47 3.22% 27.83% n.a.
  • EN

    • DE
    • EN
> B-EUR 20.02.2018 LU1477743386 151.41 0.44% 10.01% n.a.
  • EN

    • DE
    • EN
> B-CHF 20.02.2018 LU1477743113 161.10 -1.01% 19.20% n.a.
  • EN

    • DE
    • EN
> I-EUR 20.02.2018 LU1477743204 152.93 0.53% 10.88% n.a.
  • EN

    • DE
    • EN
> I-CHF 20.02.2018 LU1477743030 162.70 -0.91% 20.13% n.a.
  • EN

    • DE
    • EN
> I2-EUR 20.02.2018 LU1587979334 136.02 n.a. n.a. n.a.
  • EN

    • DE
    • EN
> I2-CHF 20.02.2018 LU1587979250 146.55 n.a. n.a. n.a.
  • EN

    • DE
    • EN
> I2-USD 20.02.2018 LU1587979177 156.95 n.a. n.a. n.a.
  • EN

    • DE
    • EN

BB Adamant Asia Pacific Healthcare (Lux)

> I-USD 20.02.2018 LU1587984680 167.91 n.a. n.a. n.a.
  • EN

    • DE
    • EN
> B-EUR 20.02.2018 LU1587985570 148.32 n.a. n.a. n.a.
  • EN

    • DE
    • EN
> B-CHF 20.02.2018 LU1587985141 157.02 n.a. n.a. n.a.
  • EN

    • DE
    • EN
> B-USD 20.02.2018 LU1587984847 167.75 n.a. n.a. n.a.
  • EN

    • DE
    • EN
> I-CHF 20.02.2018 LU1587984920 158.21 n.a. n.a. n.a.
  • EN

    • DE
    • EN
> I-EUR 20.02.2018 LU1587985224 149.17 n.a. n.a. n.a.
  • EN

    • DE
    • EN
> I2-USD 20.02.2018 LU1587984763 170.62 n.a. n.a. n.a.
  • EN

    • DE
    • EN
> I2-EUR 20.02.2018 LU1587985497 150.54 n.a. n.a. n.a.
  • EN

    • DE
    • EN
> I2-CHF 20.02.2018 LU1587985067 160.18 n.a. n.a. n.a.
  • EN

    • DE
    • EN

BB Adamant Emerging Markets Healthcare (Lux)

> I-USD 20.02.2018 LU1585228296 155.46 n.a. n.a. n.a.
  • EN

    • DE
    • EN
> B-EUR 20.02.2018 LU1585229187 141.20 n.a. n.a. n.a.
  • EN

    • DE
    • EN
> B-USD 20.02.2018 LU1585228452 154.64 n.a. n.a. n.a.
  • EN

    • DE
    • EN
> B-CHF 20.02.2018 LU1585228700 149.38 n.a. n.a. n.a.
  • EN

    • DE
    • EN
> I-EUR 20.02.2018 LU1585228882 141.94 n.a. n.a. n.a.
  • EN

    • DE
    • EN
> I-CHF 20.02.2018 LU1585228536 150.16 n.a. n.a. n.a.
  • EN

    • DE
    • EN
> I2-USD 20.02.2018 LU1585228379 155.89 n.a. n.a. n.a.
  • EN

    • DE
    • EN
> I2-EUR 20.02.2018 LU1585229005 142.05 n.a. n.a. n.a.
  • EN

    • DE
    • EN
> I2-CHF 20.02.2018 LU1585228619 150.59 n.a. n.a. n.a.
  • EN

    • DE
    • EN

News

Markets & Opinions / 16.02.2018

BB Biotech publishes its annual report for 2017.

Products & Services / 08.02.2018

Bellevue seeks capital to invest in young, innovative, Swiss biotech companies.

Markets & Opinions / 25.01.2018

Read the current issue with a focus on gene therapies.

Markets & Opinions / 19.01.2018

Mid caps overdeliver on innovation and are becoming a key upside trigger.

Markets & Opinions / 19.01.2018

Dr. Christian Koch about the fourth quarter and the full year 2017.

Markets & Opinions / 17.01.2018

BB Healthcare Trust's Paul Major anticipating another bumper year.

Markets & Opinions / 08.01.2018

Metabolic diseases: biotechnology in the battle against diabetes.

Markets & Opinions / 13.11.2017

Record of the call with our expers from the US and Asia on November 9, 2017.

Markets & Opinions / 31.10.2017

Read the issue of the 3rd quarter 2017.

Markets & Opinions / 20.10.2017

Highlights of the 3rd quarter 2017 in the video update with Dr. Christian Koch.